Todd Patrick, a longtime vaccine company executive, has been named the chairman of the board of trustees at Seattle Biomedical Research Institute. Patrick is the former president of ID Biomedical, the Vancouver, BC and Bothell, WA-based vaccine developer that was acquired by GlaxoSmithKline for $1.5 billion in 2005. Patrick has served on the SBRI board for two years, and takes the chairmanship as the nonprofit research institute prepares to advance a novel malaria vaccine candidate from the lab to its first clinical trial in early 2010.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
